Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2021 pubmed 4 citations

Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog.

Terse. Pramod S PS; Peggins. James J; Seminara. Stephanie B SB

Key Findings

  • KP-10 was well tolerated in dogs at doses up to 1,000 µg/kg daily for 14 days (NOAEL).
  • Luteinizing hormone (LH) peaked within 5 minutes after dosing and stayed elevated for about 30 minutes, with no gender differences.
  • No adverse effects were seen in clinical signs, body weight, food intake, blood work, organ histology, ECG, or respiratory rate, and no lingering effects after a 14‑day washout.

Practical Outcomes

  • For self‑experimenters, this study suggests that short‑term IV dosing of KP-10 appears safe in dogs, but human safety is still unknown. The rapid LH response shows the peptide works quickly, but the lack of lasting hormonal changes means dosing schedules would need frequent administration. Until human data emerge, KP-10 is not ready for DIY protocols aimed at reproductive or performance benefits.

Summary

A study gave dogs a peptide called kisspeptin-10 (KP-10) once a day for two weeks and found no signs of toxicity even at the highest dose tested. The peptide cleared from the blood quickly, and the hormone LH spiked right after each dose but dropped over time. The dogs stayed in a non‑reproductive state throughout the experiment, and everything returned to normal after a two‑week recovery period.

Abstract

Kisspeptin-10 (previously referred as metastin 45-54), an active fragment of the endogenous full-length kisspeptin-145, is a potential therapeutic agent for reproductive disorders such as infertility, amenorrhea, and pubertal delay. A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period. There were no overt signs of drug-related toxicity observed in clinical signs, body weights, food consumption, clinical pathology, histopathology, urinalysis, electrocardiogram, or respiratory rate. Due to very rapid clearance of the peptide, luteinizing hormone (LH) levels were measured as a surrogate marker to demonstrate KP-10 exposure. The LH response reached a maximum concentration at 5 minutes post-dose and remained relatively unchanged for at least 30 minutes after dosing with no gender effect. LH concentrations on Day 1 were generally greater than on day 14. Vaginal cytology results indicated all dogs were in anestrous throughout the dosing period. There were also no KP-10-related findings observed in recovery animals on Day 29. In conclusion, KP-10 demonstrated favorable safety profile in dog where 1,000 μg/kg dose was considered as a no-observed-adverse-effect level dose when administered IV once daily for 14 days.

Study Information

Provider

pubmed

Year

2021

Date

2021-06-14T00:00:00.000Z

DOI

10.1177/10915818211023459

Citations

4

References

26